BLUE - bluebird bio's Pricing Strength Expands Their Potential
Recent Company Background:
bluebird bio (BLUE) is one of the larger ($7.4B market cap) pure biotechs focused on the cell/gene therapy and CAR-T space. They have recently been making the rounds in the news regarding their exciting developments. Although they are a diverse biotech, looking at therapeutics addressing a wide range of rare diseases (as well as an oncology division), this article will focus primarily on their beta-thalassemia therapeutic news as well as their sickle-cell indication for the same product. They have many competitors attempting to provide a dedicated cure against sickle-cell